Literature DB >> 9453789

[Diabetic foot syndrome and its risks: amputation, handicap, high-cost sequelae].

H G Dahmen1.   

Abstract

Amputation, Handicap, High Subsequent Costs. Lack of "Outpatient Wards for Diseases Involving the Feet" in German hospitals. A Challenge to Prevention: In consequence of diabetic polyneuropathy, about 25% of all diabetics develop neuropathic foot complications often resulting in amputation (about 30,000 cases in Germany per annum). Suffering and handicaps of the patients, as well as the high costs involved (estimated at 800 million Deutsche Mark per annum) systematic prophylaxis and early identification of patients at risk are imperative. According to experts every second amputation could be avoided if treatment of diabetic foot complications is started as early as possible. To prevent expensive in-hospital treatment, an outpatient clinical treatment may be offered on an interdisciplinary basis (internist, neurologist, orthopaedist, surgeon, radiologist). About 50 "outpatient wards for diseases involving the feet" exist up to now in German hospitals. Appropriate fees, subsidy by sick funds (and if necessary by politicians) and co-operation with general practitioners, internists etc. are indispensable. Other important co-operators are the family doctors. With regard to health care, preventive activities and publicity, co-operation of the local Public Health departments would also be feasible.

Entities:  

Mesh:

Year:  1997        PMID: 9453789

Source DB:  PubMed          Journal:  Gesundheitswesen        ISSN: 0941-3790


  5 in total

1.  [Significance of microbial colonisation in materials for orthopaedic technology. New insights].

Authors:  F Kipp; K Angermeier; A Koller; H H Wetz; C Hornberg
Journal:  Orthopade       Date:  2006-11       Impact factor: 1.087

2.  Self-measurement of blood glucose in patients with type 2 diabetes: a health economic assessment.

Authors:  Christian Weber; Kurt Neeser; Berthold Schneider; Volker Lodwig
Journal:  J Diabetes Sci Technol       Date:  2007-09

Review 3.  Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a german statutory healthcare perspective.

Authors:  Kurt Neeser; Georg Lübben; Uwe Siebert; Wendelin Schramm
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

4.  Management of leg and pressure ulcer in hospitalized patients: direct costs are lower than expected.

Authors:  Ojan Assadian; Joseph S Oswald; Rainer Leisten; Peter Hinz; Georg Daeschlein; Axel Kramer
Journal:  GMS Krankenhhyg Interdiszip       Date:  2011-12-15

5.  Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective.

Authors:  Werner A Scherbaum; Gordon Goodall; Katrina M Erny-Albrecht; Massimo Massi-Benedetti; Erland Erdmann; William J Valentine
Journal:  Cost Eff Resour Alloc       Date:  2009-05-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.